Anti-interleukin-5 therapy in patients with severe asthma: from clinical trials to clinical practice

被引：1
|
作者：
Beasley, Richard [1 ,2 ]
Harper, James [1 ]
Masoli, Matthew [3 ]
机构：
[1] Med Res Inst New Zealand, Wellington 6242, New Zealand
[2] Capital & Coast Dist Hlth Board, Wellington, New Zealand
[3] Univ Exeter, Royal Devon & Exeter Hosp, Exeter, Devon, England
来源：
LANCET RESPIRATORY MEDICINE | 2020年 / 8卷 / 05期
关键词：
BENRALIZUMAB; ANTIBODY; SAFETY;
D O I：
10.1016/S2213-2600(20)30051-5
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：425 / 427
页数：4
相关论文
共 50 条
  • [31] Change of lung function in severe eosinophilic asthma undergoing treatment with anti-interleukin-5 monoclonal antibody
    Antonicelli, Leonardo
    Gobbi, Alessandro
    Bilo, Maria Beatrice
    Garritani, Maria Stella
    Brianzoni, Maria Feliciana
    Dellaca, Raffaele
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [32] Severe asthma: Characteristics of patients in clinical practice
    Sergeeva, G. R.
    Emelyanov, A. V.
    Korovina, O. V.
    Znakhurenko, A. A.
    Leshenkova, E. V.
    Kozyreva, L. V.
    Asatiani, N.
    TERAPEVTICHESKII ARKHIV, 2015, 87 (12): : 26 - 31
  • [33] Anti-Interleukin-5 Therapy in Patients with Asthma and Chronic Obstructive Pulmonary Disease Overlap: A Single-Center Review
    Saint-Pierre, M. D.
    Mavromatis, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [34] Evaluation of bronchial hyperreactivity and other functional parameters in severe asthma patients treated with anti-interleukin-5 monoclonal antibody (IL5)
    Bini, Francesco
    Grassi, Noemi
    Visca, Dina
    De Lauretis, Angelo
    SpaneNoello, Antonio
    Vaghi, Adriano
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [35] Continuous improvement of FEV1 in severe eosinophilic asthmatics on anti-interleukin-5 therapy
    Michils, Alain
    Makhoul, Jean-Pierre
    Blekic, Nathan
    Haccuria, Amaryllis
    Perez-Bogerd, Silvia
    Malinovschi, Andrei
    Van Muylem, Alain
    ALLERGY, 2024,
  • [36] Effectiveness and safety of biological therapy in patients with severe asthma in a real clinical practice
    Sergeeva, Galina R.
    V. Emelyanov, Alexander
    TERAPEVTICHESKII ARKHIV, 2024, 96 (03): : 240 - 245
  • [37] Clinical efficacy of anti-IgE therapy in adult patients with atopic severe uncontrolled asthma in real practice
    Ignatova, G. L.
    Blinova, E., V
    Zakharova, I. A.
    Kochetkova, S. A.
    Revel-Muroz, N. P.
    ALLERGY, 2018, 73 : 671 - 671
  • [38] Complete response to anti-interleukin-5 biologics in a real-life setting: results from the nationwide Danish Severe Asthma Register
    Soendergaard, Marianne Baastrup
    Hansen, Susanne
    Bjerrum, Anne-Sofie
    Hilberg, Ole
    Lock-Johansson, Sofie
    Hakansson, Kjell Erik Julius
    Ingebrigtsen, Truls Sylvan
    Johnsen, Claus Rikard
    Rasmussen, Linda Makowska
    von Bulow, Anna
    Assing, Karin Dahl
    Schmid, Johannes Martin
    Ulrik, Charlotte Suppli
    Porsbjerg, Celeste
    ERJ OPEN RESEARCH, 2022, 8 (04)
  • [39] Analysis of predictors of response to anti-IgE therapy in patients with severe atopic bronchial asthma in real clinical practice
    Fomina, Daria S.
    Mukhina, Olga A.
    Lebedkina, Marina S.
    Gadzhieva, Mirada K.
    Bobrikova, Elena N.
    Sinyavkin, Dmitry O.
    Parshin, Vasiliy V.
    Chernov, Anton A.
    Belevskiy, Andrey S.
    TERAPEVTICHESKII ARKHIV, 2022, 94 (03): : 413 - 419
  • [40] No effect of anti-interleukin-5 therapy (mepolizumab) on the atopy patch test in atopic dermatitis patients
    Oldhoff, J. M.
    Darsow, U.
    Werfel, T.
    Bihari, I. C.
    Katzer, K.
    Laifaoui, J.
    Ploetz, S.
    Kapp, A.
    Knol, E. F.
    Bruijnzeel-Koomen, C. A. F. M.
    Ring, J.
    de Bruin-Weller, M. S.
    INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2006, 141 (03) : 290 - 294
12345